GYNECOLOGIC CANCERS

Dr Alexander Olawaiye discusses the impact of the FDA approval of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Premal Thaker, MD, MS, discusses IMNN-001 boosts overall survival in advanced ovarian cancer, with bigger gains alongside PARP inhibitors, as phase 3 OVATION 3 ramps up.

Rezatapopt showed clinical activity across subgroups in patients with TP53 Y220C-mutated ovarian cancer in the phase 2 PYNNACLE trial.

Enrollment restarts in a phase 2 ovarian and clear cell gynecologic cancer study after FDA lifts hold on PD-1/CTLA-4 DART therapy.

Tisotumab vedotin plus carboplatin and pembrolizumab ± bevacizumab elicited antitumor acitivity in a phase 1/2 cervical cancer trial.

Mirvetuximab soravtansine plus carboplatin showed promise in patients with FRα-positive platinum-sensitive ovarian cancer.

The novel FRα-targeted ADC sofetabart mipitecan showed strong antitumor activity in patients with heavily pretreated platinum-resistant ovarian cancer.

Trastuzumab pamirtecan, a novel antibody-drug conjugate, showed initial efficacy signals in pretreated patients with HER2-expressing endometrial cancer.

Final ROSELLA overall survival results show adding relacorilant to nab-paclitaxel reduces risk of death by 35% in platinum-resistant ovarian cancer.

FDA grants fast track designation to SIM0505, a CDH6-targeting ADC, for platinum-resistant ovarian cancer. Phase 1 data expected at ASCO 2026.

FDA fast track status for CTIM-76 underscores the unmet need in platinum-resistant ovarian cancer.

ZW191 is engineered to bind to FRα, a cell-surface protein with high expression across several tumor types.

Final results from the phase 2 OVATION 2 trial show that adding IMNN-001 to standard chemotherapy significantly improves overall survival in newly diagnosed advanced ovarian cancer.

FDA approves relacorilant for platinum-resistant ovarian cancer, showing significant survival benefits without added safety risks in clinical trials.

FDA clears MyChoice CDx to find HRD-positive advanced ovarian cancer patients for niraparib, using BRCA and genomic instability testing.

COMPASSION-03 follow-up shows cadonilimab delivers durable survival in recurrent/metastatic cervical cancer, including PD‑L1–negative patients.

Logic-gated CAR T A2B543 enters EVEREST-2 arm 2, adding membrane-tethered IL-12 to boost solid-tumor potency while limiting toxicity.

Clinical trial data show ovarian cancer survival gaps narrow with diverse enrollment, but disparities persist after progression, spotlighting access, toxicity, and care barriers.

Phase 2 data show elenagen plus gemcitabine extends survival in platinum-resistant ovarian cancer with high CA-125, without added toxicity.

Screening rates fall as many women seek privacy and convenience; FDA‑cleared home HPV self-sampling may boost access and reduce disparities.

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, surgery, and clinic efficiency.

New data links PARP maintenance after recurrence to higher AML/MDS risk and shorter survival, pushing most use to frontline therapy.

Molecular profiling guides ovarian cancer maintenance: HRD and BRCA results steer PARP inhibitors, bevacizumab choices, and patient counseling.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.